Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing
Cancer Medicine · 2024
DOI: 10.1002/cam4.70351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Zhongbo Hu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Hospitalist Medicine Program, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Antimetabolites, Antineoplastic, Methotrexate, Precision Medicine, Stomatitis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute Cancer Center Support. CORE Grant, National Cancer Institute pediatric oncology education grant.
Abstract (Originalsprache)
Background
Oral mucositis affects about 20% of children undergoing high‐dose methotrexate (HDMTX) for acute lymphoblastic leukemia (ALL), despite existing management strategies. Personalized HDMTX dosing, adjusted by pharmacokinetics and leukemia risk, has reduced mucositis incidence, but variations still occur with similar 24‐h methotrexate levels.
Methods
This retrospective study investigated risk factors for oral mucositis under individualized methotrexate protocols. Data from patients with ≥ Grade 2 oral mucositis (CTCAE v4.0) were analyzed from the St. Jude Children's Research Hospital total 16 trial. A 1:1 case–control matching method considered age, sex, risk classification, immunophenotype, and methotrexate course. McNemar's, Bowker's symmetry, and Wilcoxon signed‐rank tests were used for statistical analyses. Risk factors for recurrent mucositis were identified in a case‐only analysis.
Results
The study found significant associations between methotrexate‐induced mucositis and new‐onset skin rashes ( p = 0.0027), fever ( p = 0.0016), neutropenic fever ( p = 0.0008), lower absolute neutrophil count ( p < 0.0001), acute kidney injury (AKI) ( p = 0.0164), delayed methotrexate clearance ( p = 0.0133), and higher 42‐h methotrexate levels ( p = 0.0179). In the standard/high‐risk group, mercaptopurine dose was also linked to mucositis ( p = 0.0495). Multivariable analysis showed that skin rashes (OR 6.5, p = 0.0016), fever (OR 2.8, p = 0.009), and neutropenia (OR 2.3, p = 0.0106) were independent risk factors for mucositis. Female sex (OR 7.12, p = 0.015) and AKI (OR 3.819, p = 0.037) were associated with recurrent mucositis.
Conclusions
Fever, skin rashes, AKI, delayed methotrexate clearance, and higher 42‐h methotrexate levels were key risk factors for HDMTX‐induced oral mucositis. Skin rashes, fever, and neutropenia were independent predictors, while female sex and AKI were linked to recurrent mucositis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospitalist Medicine Program, Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Pediatric Oncology Education Program 2023, School of Medicine, Ponce Health Sciences University, Ponce, Puerto Rico.
- Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
ORCID-Profile: Zhongbo Hu, Rushil Acharya, Sima Jeha
Förderung
- NCI NIH HHS
- National Cancer Institute Cancer Center Support. CORE Grant
- National Cancer Institute pediatric oncology education grant
Zitieren
APA
Hu, Z., Escalera-Joy, A. M., Ashcraft, E., Acharya, R., Jeha, S., Cheng, C., & Pui, C. H. (2024). Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing. Cancer Medicine. https://doi.org/10.1002/cam4.70351
Vancouver
Hu Z, Escalera-Joy AM, Ashcraft E, Acharya R, Jeha S, Cheng C, et al. Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing. Cancer Medicine. 2024. doi:10.1002/cam4.70351
BibTeX
@article{Hu2024,
author = {Hu, Zhongbo and Escalera-Joy, Andrea M and Ashcraft, Emily and Acharya, Rushil and Jeha, Sima and Cheng, Cheng and Pui, Ching-Hon},
title = {Clinical Risk Factors for High‐Dose Methotrexate‐Induced Oral Mucositis Following Individualized Dosing},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70351}
}
EUVIMED